Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

被引:1
作者
Singh, Simron [1 ]
Hope, Thomas A. [2 ]
Bergsland, Emily B. [3 ]
Bodei, Lisa [4 ]
Bushnell, David L. [5 ]
Chan, Jennifer A. [6 ]
Chasen, Beth R. [7 ]
Chauhan, Aman [8 ]
Das, Satya [9 ]
Dasari, Arvind [10 ]
Del Rivero, Jaydira [11 ]
El-Haddad, Ghassan [12 ]
Goodman, Karyn A. [13 ]
Halperin, Daniel M. [10 ]
Lewis, Mark A. [14 ]
Lindwasser, O. Wolf [15 ]
Myrehaug, Sten [16 ]
Raj, Nitya P.
Reidy-Lagunes, Diane L. [17 ]
Soares, Heloisa P. [18 ]
Strosberg, Jonathan R. [19 ]
Kohn, Elise C. [20 ]
Kunz, Pamela L. [21 ,22 ]
机构
[1] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada
[2] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA
[5] Univ Iowa, Dept Radiol, Iowa City, IA USA
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX USA
[8] Univ Miami, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Oncol R&D AstraZeneca, Late Stage Dev, Gaithersburg, MD USA
[10] Univ Texas MD Anderson Canc Ctr, Dept GI Oncol, Div Canc Med, Houston, TX USA
[11] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Diagnost Imaging & Intervent Radiol, Tampa, FL USA
[13] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Radiat Oncol, New York, NY USA
[14] Intermt Hlth, Dept Med, Salt Lake City, UT USA
[15] NCI, Coordinating Ctr Clin Trials, Bethesda, MD USA
[16] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada
[17] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[18] Huntsman Canc Inst Univ Utah, Dept Med, Salt Lake City, UT USA
[19] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA
[20] NCI, Bethesda, MD USA
[21] Yale Univ, Dept Med, Sch Med, New Haven, CT USA
[22] Yale Sch Med, Yale Canc Ctr, Dept Med, Sect Med Oncol, 333 Cedar St, POB 208028, New Haven, CT 06520 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2023年 / 115卷 / 09期
关键词
RECEPTOR RADIONUCLIDE THERAPY; RESISTANT PROSTATE-CANCER; PHASE-II; SOMATOSTATIN RECEPTOR; RADIATION-THERAPY; PLUS; LU-177-DOTATATE; PEMBROLIZUMAB; COMBINATION; EVEROLIMUS;
D O I
10.1093/jnci/djad096
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated neuroendocrine tumors (NETs) have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of Lu-177-DOTATATE for treatment of gastroenteropancreatic-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trial planning meeting in 2021 with multidisciplinary experts from academia, the federal government, industry, and patient advocates to develop NET clinical trials in the era of PRRT. Key clinical trial recommendations for development included 1) PRRT re-treatment, 2) PRRT and immunotherapy combinations, 3) PRRT and DNA damage repair inhibitor combinations, 4) treatment for liver-dominant disease, 5) treatment for PRRT-resistant disease, and 6) dosimetry-modified PRRT.
引用
收藏
页码:1001 / 1010
页数:10
相关论文
共 78 条
  • [11] Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study
    Braat, Arthur J. A. T.
    Bruijnen, Rutger C. G.
    van Rooij, Rob
    Braat, Manon N. G. J. A.
    Wessels, Frank J.
    van Leeuwaarde, Rachel S.
    van Treijen, Mark J. C.
    de Herder, Wouter W.
    Hofland, Johannes
    Tesselaar, Margot E. T.
    de Jong, Hugo W. A. M.
    Lam, Marnix G. E. H.
    [J]. LANCET ONCOLOGY, 2020, 21 (04) : 561 - 570
  • [12] Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
    Brabander, Tessa
    van der Zwan, Wouter A.
    Teunissen, Jaap J. M.
    Kam, Boen L. R.
    Feelders, Richard A.
    de Herder, Wouter W.
    van Eijck, Casper H. J.
    Franssen, Gaston J. H.
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4617 - 4624
  • [13] A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
    Capdevila, J.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent, M.
    Custodio, A.
    Cubillo, A.
    Alonso, V.
    Alonso Gordoa, T.
    Carmona-Bayonas, A.
    Crespo, G.
    Blanco-Codesido, M.
    Jimenez-Fonseca, P.
    Viudez, A.
    La Casta Munoa, A.
    Sevilla, I.
    Llanos, M.
    Segura, A.
    Hernando-Cubero, J.
    Manzano, J. L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S770 - S771
  • [14] Caplin ME, 2014, NEW ENGL J MED, V371, P224, DOI [10.1056/NEJMc1409757, 10.1056/NEJMoa1316158]
  • [15] Combination Strategies to Improve Targeted Radionuclide Therapy
    Chan, Tiffany G.
    O'Neill, Edward
    Habjan, Christine
    Cornelissen, Bart
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1544 - 1552
  • [16] Outcomes after high-dose radiation in the management of neuroendocrine neoplasms
    Chen, Katherine S.
    Lawhn-Heath, Courtney
    Behr, Spencer
    Juarez, Roxanna
    Whitman, Julia
    Paciorek, Alan
    Nakakura, Eric K.
    Fidelman, Nicholas
    Feng, Mary Uan-Sian
    Bergsland, Emily K.
    Anwar, Mekhail
    [J]. PLOS ONE, 2021, 16 (06):
  • [17] Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
    Chung, Hyun Cheol
    Piha-Paul, Sarina A.
    Lopez-Martin, Jose
    Schellens, Jan H. M.
    Kao, Steven
    Miller, Wilson H., Jr.
    Delord, Jean-Pierre
    Gao, Bo
    Planchard, David
    Gottfried, Maya
    Zer, Alona
    Jalal, Shadia I.
    Penel, Nicolas
    Mehnert, Janice M.
    Matos, Ignacio
    Bennouna, Jaafar
    Kim, Dong-Wan
    Xu, Lei
    Krishnan, Suba
    Norwood, Kevin
    Ott, Patrick A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 618 - 627
  • [18] Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
    Cullinane, Carleen
    Waldeck, Kelly
    Kirby, Laura
    Rogers, Buck E.
    Eu, Peter
    Tothill, Richard W.
    Hicks, Rodney J.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [19] Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
    Dasari, Arvind
    Shen, Chan
    Halperin, Daniel
    Zhao, Bo
    Zhou, Shouhao
    Xu, Ying
    Shih, Tina
    Yao, James C.
    [J]. JAMA ONCOLOGY, 2017, 3 (10) : 1335 - 1342
  • [20] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Arsenault, Frederic
    Saighi, Nassim
    Bouchard, Louis-Olivier
    Beaulieu, Alexis
    Beauregard, Jean-Mathieu
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 728 - 742